Biocryst Pharmaceuticals (BCRX) Assets Average (2011 - 2026)

Biocryst Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $489.6 million for Q1 2026.

• Quarterly Assets Average rose 0.9% year-over-year to $489.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $489.6 million (up 0.9% YoY) and the FY2025 annual result came in at $502.3 million, changed 0.28% from the prior year.
• Assets Average was $489.6 million for Q1 2026 at Biocryst Pharmaceuticals, up from $480.3 million in the prior quarter.
• Across five years, Assets Average topped out at $557.9 million in Q1 2022 and bottomed at $451.8 million in Q3 2025.
• A 5-year average of $504.3 million and a median of $492.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 96.88% — and 2024, when it retreated 9.55%.
• Biocryst Pharmaceuticals' Assets Average stood at $554.3 million in 2022, then fell by 6.2% to $519.9 million in 2023, then decreased by 5.6% to $490.8 million in 2024, then retreated by 2.15% to $480.3 million in 2025, then gained by 1.94% to $489.6 million in 2026.
• Business Quant data shows BCRX's Assets Average at $489.6 million in Q1 2026, $480.3 million in Q4 2025, and $451.8 million in Q3 2025.